UNQ Holdings Limited (stock code: 2177) has renewed its 2023 Products Procurement Framework Agreement with Transcosmos Inc. (“TCI”) through a new 2026 Products Procurement Framework Agreement. TCI holds approximately 34.52% of UNQ Holdings Limited’s total issued shares and is therefore a controlling shareholder, making this arrangement a continuing connected transaction under Chapter 14A of the Listing Rules.

The new agreement will run from 1 January 2026 to 31 December 2028. Under its terms, UNQ Holdings Limited will purchase over-the-counter pharmaceutical and healthcare products introduced by TCI’s network of Japanese brand partners, with the consideration based on a cost-plus markup not exceeding 8%. Historical transaction amounts were recorded at approximately RMB54.96 million for 2023, RMB35.63 million for 2024, and RMB54.11 million for the nine months ended 30 September 2025. Reflecting anticipated business growth, the proposed annual caps stand at RMB200 million for 2026, RMB250 million for 2027, and RMB300 million for 2028.

In light of the size of these transactions, they are subject to annual reporting, announcement, and independent shareholders’ approval requirements. An Independent Board Committee has been established to review the agreement, with DL Securities appointed as Independent Financial Adviser. A circular detailing the transaction terms, recommendations from the Independent Board Committee, and notice of the Extraordinary General Meeting is scheduled to be dispatched to shareholders by no later than 28 November 2025.